Details for New Drug Application (NDA): 209128
✉ Email this page to a colleague
The generic ingredient in DSUVIA is sufentanil citrate. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the sufentanil citrate profile page.
Summary for 209128
Tradename: | DSUVIA |
Applicant: | Vertical Pharms |
Ingredient: | sufentanil citrate |
Patents: | 21 |
Pharmacology for NDA: 209128
Mechanism of Action | Full Opioid Agonists |
Medical Subject Heading (MeSH) Categories for 209128
Suppliers and Packaging for NDA: 209128
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128 | NDA | AcelRx Pharmaceuticals, Inc. | 61621-430 | 61621-430-01 | 1 TABLET in 1 POUCH (61621-430-01) |
DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128 | NDA | AcelRx Pharmaceuticals, Inc. | 61621-430 | 61621-430-11 | 10 TABLET in 1 CARTON (61621-430-11) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;SUBLINGUAL | Strength | EQ 0.03MG BASE | ||||
Approval Date: | Nov 2, 2018 | TE: | RLD: | Yes | |||||
Patent: | 10,245,228 | Patent Expiration: | Jan 5, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF ACUTE PAIN | ||||||||
Patent: | 10,342,762 | Patent Expiration: | Jan 5, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 10,507,180 | Patent Expiration: | Jan 5, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF ACUTE PAIN |
Complete Access Available with Subscription